SCHEMBL5057260

SCHEMBL5057260

CCCCOC(=O)c1ccc2c(c1)N=C(c1ccc(Cl)s1)c1c(ccc(F)c1C(N)=O)S2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.41
CNR2 P34972 2/20 0.41
LMNA P02545 2/20 0.34
CYP1A2 P05177 2/20 0.34
TSHR P16473 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
PDE4D Q08499 1/20 0.34
ESR1 P03372 5/20 0.34
NPSR1 Q6W5P4 2/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP2D6 P10635 1/20 0.33
MAPK1 P28482 1/20 0.33
NR1H2 P55055 1/20 0.33
RNASEL Q05823 1/20 0.33
TP53 P04637 1/20 0.32
STS P08842 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062662 0.88 CNR1 (0.47) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5063096 0.87 CNR1 (0.44) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5057256 0.86 CNR1 (0.42) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5057771 0.85 CNR1 (0.46) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5054181 0.85 CNR1 (0.41) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5064791 0.77 CNR1 (0.56) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5054098 0.75 CNR1 (0.45) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5064769 0.75 CNR1 (0.49) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5057364 0.75 CNR1 (0.51) CNR1CNR2LMNACYP1A2TSHR
SCHEMBL5057665 0.74 CNR1 (0.51) CNR1CNR2CYP2C19CYP2C9NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH CNR1 1/4885CNR2 2/4885LMNA 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.